Neutropenia in colorectal cancer treated with oxaliplatin-based hyperthermic intraperitoneal chemotherapy: An observational cohort study

Table 2 Univariate and multivariate Cox proportional regression analysis with disease-free survival as endpoint

	Univariate, hazard ratio	P value	Multivariate, hazard ratio	P value
Age (yr)	1.00 (CI: 0.99-1.01)	0.7
Gender male/female (n)	1.19 (CI: 0.89-1.59)	0.2
Colon/Rectum	0.81 (CI: 0.11-5.77)	1.0
Synchronous/metachronous	0.90 (CI: 0.68-1.20)	0.49
Neoadjuvant for PM disease	1.06 (CI: 0.79-1.41)	0.7
Node positive disease primary	1.16 (CI: 0.83-1.61)	0.52
Poor differentiation	1.08 (CI: 0.78-1.49)	0.82
PCI	1.03 (CI: 1.01-1.04)	0.0005	1.02 (CI: 1.00-1.04)	0.033
Liver metastases	1.56 (CI: 1.06-2.30)	0.02	1.52 (CI: 1.03-2.25)	0.016
CC score 0 vs 1-3	1.91 (CI: 1.36-2.67)	0.0001	1.66 (CI: 1.12-2.46)	0.011
EPIC administration	0.92 (CI: 0.56-1.50)	0.73
OX HIPEC; OXIRI HIPEC	Reference 0.74 (0.51-1.07)	0.11
Operating time	1.00 (CI: 1.00-1.00)	0.04	1.00 (CI: 1.00-1.00)	0.25
Any-grade neutropenia	0.61 (CI: 0.38-0.98)	0.02	0.58 (CI: 0.36-0.95)	0.031
Adjuvant chemotherapy given	1.07 (CI: 0.80-1.44)	0.37

PM: Peritoneal metastases; PCI: Peritoneal cancer index; CC: Completeness of cytoreduction; EPIC: Early postoperative intraperitoneal chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy; OX: Oxaliplatin; IRI: Irinotecan.